Indicates neurofeedback has mechanistic plausibility and translational potential but currently insufficient, underpowered clinical evidence—prioritizing larger, standardized trials and standardized effect-size reporting could determine its real therapeutic value for PD.

Useful for guiding patient-centered outcome selection and trial/endpoints design and for informing clinical care priorities, but offers limited mechanistic or therapeutic-discovery insights for novel drug development.

Establishes a powerful, scalable resource for genetic analyses, risk stratification, biomarker discovery, and sex-specific research that can enable target identification and therapeutic cohort recruitment, though its cross-sectional, self-reported design limits immediate mechanistic or…

Although not mechanistic, the study identifies clinically measurable pain phenotypes linked to cognitive decline that could help stratify patients, prioritize symptom-targeted interventions, and refine inclusion criteria for trials addressing cognition or pain in Parkinson's disease.

Offers clinically actionable data for patient selection, risk stratification, and post-DBS monitoring that can guide trial design and adjunctive therapeutic strategies to mitigate late cognitive decline, but provides limited mechanistic insight for direct drug-discovery targets.

While not offering therapeutic mechanisms or targets, the low-cost, sensitive dopamine sensor could be a useful tool for preclinical Parkinson's research and neurotransmitter monitoring, enabling better measurement of dopaminergic changes in experimental models.

While it offers little mechanistic or therapeutic target insight, the study underscores a measurable, common caregiver/family burden that is important for designing clinical care, support services, and incorporating family-reported outcomes into PD trials and care pathways.

This paper provides little direct value for Parkinson's therapeutic discovery because it offers no mechanistic or biomarker targets, but its note that CDT has moderate sensitivity for Parkinson's-related major neurocognitive disorder may inform clinical screening or cohort selection in dementia…

This supports ECT as a clinically useful symptomatic treatment for severe neuropsychiatric manifestations in LBD when pharmacotherapy is limited, but it offers limited mechanistic or therapeutic-discovery insights for Parkinson's disease drug development.

By tying familial PD genes to mitophagy dysfunction, the paper reinforces a mechanistic, druggable axis for therapeutic targeting and biomarker development, though as a review its direct experimental or translational novelty is limited.

By linking dynamic propagation patterns to specific cellular and transcriptomic features (proteostasis, metabolism, monoaminergic identity), the work highlights actionable molecular and cellular correlates of regional vulnerability that can guide target prioritization, biomarker development, and…

By enabling standardized, strain-sensitive biochemical diagnosis and robust patient stratification, optimized α-syn SAAs can directly improve clinical trial design, target engagement assessment, and development of α-synuclein–directed therapies.

Because DJ-1 is a Parkinson’s-linked, redox-sensitive protein, the mechanistic insights and general computational protocol could inform strategies to modulate DJ-1 stability or redox state for neuroprotective therapeutic development.

Provides a noninvasive, repeatable MRI biomarker that could improve diagnostic stratification of clinically uncertain parkinsonian patients and help select/enrich cohorts for therapeutic trials, though it does not address molecular disease mechanisms or treatment targets.

By revealing photoreceptor structural shifts and lower mitochondria-rich EZ reflectivity, this noninvasive imaging approach offers a potential biomarker for metabolic/mitochondrial involvement in PD that could support patient stratification, monitoring, and therapeutic hypotheses targeting…

This paper highlights a circuit-level, exercise-responsive mechanism (cortical transition coding) that could serve as a biomarker or target for non-pharmacological interventions and neuromodulation strategies in PD, providing moderate translational value though it lacks direct molecular therapeutic…

Provides useful synthesis on tau–alpha-synuclein interactions and shared pathogenic pathways that could inform Parkinson's therapeutic target selection or combination strategies, but is primarily conceptual and lacks direct actionable interventions or biomarkers.

The paper presents a novel, testable conceptual framework that could point to new biomarkers and interventions (glycocalyx-targeting therapies, ion modulation, microbiome approaches) but is currently speculative and lacks direct experimental or clinical validation.

Highlights knee OA as a potentially modifiable risk factor that could steer mechanistic work on peripheral inflammation/systemic mediators and motivate prevention or repurposing strategies to lower PD risk.

The study supplies population-level evidence that liver dysfunction modestly correlates with PD risk and highlights liver-related biomarkers that merit mechanistic and translational follow-up, but it is observational and does not provide causal pathways or immediate therapeutic targets for…

The paper provides limited mechanistic or therapeutic leads but is valuable for prioritizing public-health resources and highlighting the urgent need to scale translational and clinical Parkinson's research and care in China due to a large recent rise in PD-related burden.

Moderately high translational value because GLP-1RAs are an already available, mechanism-plausible repurposing class that showed clinically meaningful motor effects in some trials, supporting larger, longer, biomarker-informed trials despite current heterogeneity and tolerability issues.

It highlights a promising cell-based regenerative approach that could inform PD neuroprotection/transplant strategies, but as a broad preclinical review lacking PD-specific mechanistic targets or actionable translational data its immediate value for Parkinson's drug discovery is modest.

Links between GBA1 risk variants and accelerated non-motor progression reinforce lysosomal dysfunction as a therapeutically actionable axis and justify using GBA1 status for trial stratification or targeting, but the results are exploratory and need independent replication before clinical…

By placing SARM1 at the intersection of NAD+ metabolism, PARP1-mediated DNA damage responses, and excitotoxic/MPP+-induced dopaminergic death, the study identifies a druggable, translationally relevant target with strong potential for Parkinson's neuroprotection strategies.